215 reports of this reaction
2.6% of all LOXAPINE reports
#4 most reported adverse reaction
COMA is the #4 most commonly reported adverse reaction for LOXAPINE, manufactured by Actavis Pharma, Inc.. There are 215 FDA adverse event reports linking LOXAPINE to COMA. This represents approximately 2.6% of all 8,319 adverse event reports for this drug.
Patients taking LOXAPINE who experience coma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COMA is a less commonly reported adverse event for LOXAPINE, but still significant enough to appear in the safety profile.
In addition to coma, the following adverse reactions have been reported for LOXAPINE:
The following drugs have also been linked to coma in FDA adverse event reports:
COMA has been reported as an adverse event in 215 FDA reports for LOXAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COMA accounts for approximately 2.6% of all adverse event reports for LOXAPINE, making it a notable side effect.
If you experience coma while taking LOXAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.